Holen Sie sich die Stockscreener-App
16.22
4.71%
0.73
Handel nachbörslich:
16.25
0.03
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca
Aurinia launches trial combining lupus nephritis treatments - Investing.com
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo
Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - AD HOC NEWS
Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
AUPHAurinia Pharmaceuticals Inc Latest SEC Filings - Finviz
Document - SEC.gov
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why - Yahoo Finance
If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo
Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey
IKAP Forecast — Price Target — Prediction for 2027 - TradingView
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Aurinia Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:AUPH) - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Enterprise value to EBIT forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Price to earnings forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Aurinia Pharmaceuticals Inc. Actuals & Estimates (SWB:IKAP) - TradingView
AUPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Price to book forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView
Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Price to sales forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
Price to book forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4 - TradingView
5 Small Drug Stocks to Invest in Amid a Biotech Comeback - The Globe and Mail
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last? - Yahoo Finance
Aurinia Pharmaceuticals hits new 52-week high, shares extend strong NASDAQ run - AD HOC NEWS
Aurinia Pharmaceuticals stock hits 52-week high at 17.44 USD - Investing.com
Aurinia Pharmaceuticals stock hits 52-week high at 17.44 USD By Investing.com - Investing.com South Africa
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Understanding Momentum Shifts in (AUPH) - Stock Traders Daily
Aurinia Pharmaceuticals Stockanalyst focus and sector check at week’s end - AD HOC NEWS
How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors - simplywall.st
Investors - Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating - ChartMill
Aurinia Pharmaceuticals and Four More Stocks See Activist Action - Barron's
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation - Yahoo Finance
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options - Stock Titan
Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036 - Stock Titan
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant - Stock Titan
Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67 - Stock Titan
Avoiding Lag: Real-Time Signals in (AUPH) Movement - Stock Traders Daily
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million - AOL.com
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook - Sahm
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):